¼¼°èÀÇ À¯Ã¼ »ý°Ë ½ÃÀå
Fluid Biopsy
»óǰÄÚµå : 1758765
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 282 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,121,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,364,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ À¯Ã¼ »ý°Ë ½ÃÀåÀº 2030³â±îÁö 210¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 114¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ À¯Ã¼ »ý°Ë ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 10.6%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 210¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ Æó¾ÏÀº CAGR 12.4%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 82¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯¹æ¾Ï ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 8.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 31¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 14.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ À¯Ã¼ »ý°Ë ½ÃÀåÀº 2024³â¿¡ 31¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 44¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 14.7%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 7.5%¿Í 9.5%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 8.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ À¯Ã¼ »ý°Ë ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

À¯Ã¼ »ý°ËÀÌ ¾Ï Áø´ÜÀÇ ÆÄ±«ÀûÀÎ ÈûÀ¸·Î ºÎ»óÇϰí ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

¾×ü»ý°ËÀ¸·Îµµ ¾Ë·ÁÁø À¯Ã¼ »ý°ËÀº ±âÁ¸ÀÇ Á¶Á÷ »ý°ËÀ» ´ëüÇÒ ¼ö ÀÖ´Â ºñħ½ÀÀû ¹æ¹ýÀ» Á¦°øÇÔÀ¸·Î½á ¾Ï Áø´Ü ¹× Áúº´ ¸ð´ÏÅ͸µ¿¡ º¯È­¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. ü¾× »ý°ËÀº »ýü¾×(ÁÖ·Î Ç÷¾×)¿¡¼­ ¼øÈ¯ Á¾¾ç DNA(ctDNA), ¼øÈ¯ Á¾¾ç ¼¼Æ÷(CTC), ¿¢¼ÒÁ», ¸¶ÀÌÅ©·Î RNA µî Á¾¾ç À¯·¡ ¼ººÐÀ» ºÐ¼®ÇÏ¿© ¾ÏÀÇ Á¶±â ¹ß°ß, ½Ç½Ã°£ Áúº´ ÃßÀû, Ä¡·á È¿°ú Æò°¡¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¿Ü°úÀû »ùÇøµ ¾øÀ̵µ Á¾¾çÀÇ ÀÌÁú¼ºÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ´Â ´É·ÂÀº ÀüÀ̼º Á¾¾çÀ̳ª Á¢±ÙÇϱ⠾î·Á¿î Á¾¾ç ȯ°æ¿¡¼­ ƯÈ÷ °¡Ä¡°¡ ÀÖ½À´Ï´Ù.

ƯÈ÷ Æó¾Ï, À¯¹æ¾Ï, ´ëÀå¾Ï, Àü¸³¼±¾Ï µî ´Ù¾çÇÑ ¾ÏÁ¾¿¡¼­ ¹Ì¼¼ÀÜÁ¸Áúȯ(MRD)À» °ËÃâÇϰí, ½Ç¿ëÀûÀÎ µ¹¿¬º¯À̸¦ È®ÀÎÇϸç, ¸ÂÃã Ä¡·á¹ýÀ» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀ» ÁÙ ¼ö ÀÖÀ¸¹Ç·Î Á¾¾çÇп¡¼­ °¢±¤¹Þ°í ÀÖ½À´Ï´Ù. ÀýÂ÷Àû À§Çè°ú °ø°£Àû Á¦¾àÀ¸·Î ÀÎÇØ Á¦ÇÑµÉ ¼ö ÀÖ´Â Á¶Á÷ »ý°Ë°ú ´Þ¸®, À¯Ã¼ »ý°ËÀº Áúº´ÀÌ ÁøÇàµÇ´Â µ¿¾È ¹Ýº¹ÀûÀ¸·Î »ùÇøµÇÒ ¼ö ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á°¡ °è¼Ó ¹ßÀüÇϰí ÀÖ´Â °¡¿îµ¥, À¯Ã¼ »ý°ËÀº ¿ªµ¿ÀûÀÎ Á¾¾ç ÇÁ·ÎÆÄÀϸµ°ú Ä¡·á Á¶Á¤¿¡ ÇʼöÀûÀÎ ÅøÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¾î¶² ±â¼ú Çõ½ÅÀÌ À¯Ã¼ »ý°ËÀÇ °¡´É¼ºÀ» ³ÐÈ÷°í Àִ°¡?

ºÐÀÚ»ý¹°ÇÐ, À¯Àüü ½ÃÄö½Ì, µðÁöÅÐ PCRÀÇ ±â¼úÀû ¹ßÀüÀº À¯Ã¼ »ý°ËÀÇ Á¤È®¼º°ú ÀÓ»óÀû À¯¿ë¼ºÀ» Å©°Ô È®´ëÇß½À´Ï´Ù. Â÷¼¼´ë ¿°±â¼­¿­ºÐ¼®(NGS) Ç÷§ÆûÀº ÇöÀç ctDNAÀÇ Àúºóµµ µ¹¿¬º¯À̸¦ ¹Î°¨ÇÏ°Ô °ËÃâÇÒ ¼ö ÀÖÀ¸¸ç, Á¾¾ç°ú °ü·ÃµÈ À¯Àüü º¯È­¸¦ Á¶±â¿¡ È®ÀÎÇÒ ¼ö ÀÖÀ¸¸ç, Droplet digital PCR(ddPCR)°ú BEAMing(Beads, Emulsion, Amplification, Magnetics)Àº µ¹¿¬º¯ÀÌ °ËÃâÀ» À§ÇÑ »õ·Î¿î ¹æ¹ýÀ» Á¦½ÃÇÕ´Ï´Ù. Amplification, Magnetics)°¡ µ¹¿¬º¯ÀÌ Á¤·®È­¿¡ Ȱ¿ëµÇ¾î Á¾¾çÀÇ ÁßÁõµµ ¹× Ä¡·á ¹ÝÀÀÀ» Àå±âÀûÀ¸·Î ÃßÀûÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º ±â¹Ý Ç÷§Æû°ú CTC ³óÃà ±â¼úÀº Ç÷¾× »ùÇÿ¡¼­ Èñ±Í ¼¼Æ÷ ¹× ÀÔÀÚÀÇ Æ÷ȹ È¿À²À» Çâ»ó½Ãŵ´Ï´Ù. µ¿½Ã¿¡ AI ±â¹Ý µ¥ÀÌÅÍ ºÐ¼® ÅøÀº º¹ÀâÇÑ ºÐÀÚ ½Ã±×´ÏóÀÇ ½Å¼ÓÇÑ ºÐ¼®À» ÃËÁøÇÏ¿© ½Ç½Ã°£ ÀÓ»óÀû ÀÇ»ç°áÁ¤À» Áö¿øÇÕ´Ï´Ù. ¼Òº¯, ³úô¼ö¾×, Ÿ¾×À» Æ÷ÇÔÇÑ ¿©·¯ ü¾× À¯ÇüÀÇ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ´ÙÁßÈ­ ¹× ÅëÇÕÀÇ ¹ßÀüÀ¸·Î À¯Ã¼ »ý°ËÀÇ Àû¿ë ¹üÀ§´Â Á¾¾çÇп¡ ±¹ÇѵÇÁö ¾Ê°í »êÀü °Ë»ç, Àå±â ÀÌ½Ä ¸ð´ÏÅ͸µ, °¨¿° ¸ð´ÏÅ͸µ°ú °°Àº ´Ù¸¥ ¿µ¿ªÀ¸·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù.

À¯Ã¼ »ý°ËÀÇ µµÀÔÀÌ °¡¼ÓÈ­µÇ°í ÀÖ´Â ÀÓ»ó ¹× Ä¡·á ºÐ¾ß´Â?

ü¾× »ý°ËÀº ÁÖ·Î ¾Ï ºÐ¾ß¿¡¼­ Ȱ¿ëµÇ°í ÀÖÀ¸¸ç, Á¶±â ¾Ï °ËÁø, µ¿¹Ý Áø´Ü, ³»¼º µ¹¿¬º¯ÀÌ °ËÃâÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ºñ¼Ò¼¼Æ÷Æó¾Ï(NSCLC)¿¡¼­´Â EGFR µ¹¿¬º¯À̸¦ °ËÃâÇϰí Ç¥Àû Ä¡·áÀÇ »ç¿ëÀ» À¯µµÇϱâ À§ÇØ Ã¼¾× »ý°ËÀÌ ÀÏ»óÀûÀ¸·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. À¯¹æ¾Ï°ú Àü¸³¼±¾Ï ¿ª½Ã ¹Ýº¹ÀûÀÎ ¿µ»ó Áø´ÜÀ̳ª ¼ö¼ú ¾øÀÌ È£¸£¸ó ¼ö¿ëü »óÅÂ¿Í ÀüÀÌ ÁøÇàÀ» ¸ð´ÏÅ͸µÇÏ´Â µ¥ ÀÖÀ¸¸ç, ¿¬¼Ó ü¾× »ý°ËÀÌ µµ¿òÀÌ µÇ´Â Áß¿äÇÑ ºÐ¾ßÀÔ´Ï´Ù.

°íÇü¾Ï ¿Ü¿¡µµ Ç÷¾× ¾Ç¼º Á¾¾ç, ƯÈ÷ ¹éÇ÷º´°ú ¸²ÇÁÁ¾¿¡¼­ ctDNA ±â¹Ý ¹Ì¼¼ÀÜÁ¸Áúȯ °ËÃâÀÇ ÇýÅÃÀ» ¹Þ±â ½ÃÀÛÇß½À´Ï´Ù. ÀÓ»ó½ÃÇè¿¡¼­´Â ȯÀÚ¸¦ °èÃþÈ­Çϰí, ¾à¹°ÀÇ È¿´ÉÀ» Æò°¡Çϰí, ºÐÀÚ ¹ÝÀÀ°ú ÀÓ»ó °á°ú¸¦ ¿¬°ü½Ã۱â À§ÇØ ÀϹÝÀûÀ¸·Î ü¾× »ý°Ë Æò°¡ º¯¼ö°¡ µµÀԵǰí ÀÖ½À´Ï´Ù. ÇÑÆí, ¸é¿ªÁ¾¾çÇп¡µµ Àû¿ëÀÌ È®´ëµÇ°í ÀÖÀ¸¸ç, ¿¬±¸ÀÚµéÀº ü¾× »ý°ËÀ» »ç¿ëÇÏ¿© Á¾¾ç µ¹¿¬º¯ÀÌ ºÎÇÏ(TMB)¸¦ Æò°¡Çϰí, üũÆ÷ÀÎÆ® ¾ïÁ¦Á¦¿¡ ´ëÇÑ ¹ÝÀÀÀ» ¿¹ÃøÇß½À´Ï´Ù. ü¾× »ý°ËÀÇ ¹ü¿ë¼º°ú È®À强Àº Áý´Ü ¼±º°°Ë»ç ±¸»ó°ú ÇöÀå Áø´Ü ÇÁ·¹ÀÓ¿öÅ©¿¡¼­ Æø³Ð°Ô Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù.

À¯Ã¼ »ý°Ë ½ÃÀåÀÇ ¼ºÀåÀ» Áö¿øÇÏ´Â ÁÖ¿ä ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

À¯Ã¼ »ý°Ë ½ÃÀåÀÇ ¼ºÀåÀº ÀÓ»óÀû À¯¿ë¼º, ±â¼úÀû ¼º¼÷µµ, ÀÇ·á ½Ã½ºÅÛÀÇ ¿ä±¸¿¡ ±â¹ÝÇÑ ¸î °¡Áö ¼ö·Å ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎÀº ½Ã¼ú°ú °ü·ÃµÈ ÇÕº´ÁõÀ» ÁÙÀÌ°í ºó¹øÇÑ Áúº´ ¸ð´ÏÅ͸µÀ» °¡´ÉÇÏ°Ô ÇÏ´Â ºñħ½ÀÀûÀ̰í ȯÀÚ Ä£È­ÀûÀÎ Áø´Ü Åø¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ÀÔ´Ï´Ù. ÀÌ´Â ¸ÂÃãÇü ÀÇ·á, Á¶±â °³ÀÔ, °á°ú ±â¹Ý Ä¡·á ¸ðµ¨À» ÁöÁöÇÏ´Â ¼¼°è µ¿Çâ°ú ÀÏÄ¡ÇÕ´Ï´Ù.

÷´Ü ½ÃÄö½Ì ±â¼úÀÌ Àú·ÅÇÏ°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¸é¼­ À¯Ã¼ »ý°ËÀº ÀÓ»óÀÇ¿Í Áø´Ü ½ÇÇè½Ç ¸ðµÎ¿¡ ´õ ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. Àü ¼¼°è ¾Ï ¹ßº´·ü Áõ°¡¿Í Àû½Ã¿¡ ºÐÀÚ ¼öÁØÀÇ ÀÇ»ç°áÁ¤ Áö¿øÀÇ Çʿ伺ÀÌ ¸Â¹°·Á ÀÓ»ó Àû¿ëÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ½ÃÀå¿¡¼­ ¾×ü»ý°Ë ±â¹Ý µ¿¹Ý Áø´Ü¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú ÁÖ¿ä ½ÃÀå¿¡¼­ÀÇ »óȯ Áö¿øÀº Ç¥ÁØ Á¾¾çÇÐ ¿öÅ©Ç÷ο쿡¼­ ¾×ü»ý°ËÀÇ ¿ªÇÒÀ» ´õ¿í °ø°íÈ÷ Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¤¹Ð Á¾¾çÇÐ ¿¬±¸, ¹ÙÀÌ¿À Á¦¾à»ç¿ÍÀÇ °øµ¿ ¿¬±¸, ½ºÅ¸Æ®¾÷ÀÇ Çõ½Å¿¡ ´ëÇÑ È°¹ßÇÑ ÅõÀÚ´Â À¯Ã¼ »ý°Ë ¿ëµµÀÇ ¿µ¿ªÀ» °è¼Ó È®ÀåÇÏ´Â ¿ªµ¿ÀûÀÌ°í °æÀïÀûÀÎ »ýŰ迡 ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ä¼ÒµéÀÌ °áÇյǾî À¯Ã¼ »ý°ËÀº Áúº´ ¹ß°ß°ú ¸ÂÃã Ä¡·áÀÇ ¹Ì·¡¸¦ º¯È­½ÃŰ´Â Á¸Àç°¡ µÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

ÀûÀÀÁõ(Æó¾Ï, À¯¹æ¾Ï, ´ëÀå¾Ï, ±âŸ ÀûÀÀÁõ); À¯Çü(¼øÈ¯Á¾¾ç¼¼Æ÷, ¼øÈ¯ Á¾¾ç DNA, ¹«¼¼Æ÷ DNA)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ ÇÕ°è 42»ç)

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å¿¡ ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Fluid Biopsy Market to Reach US$21.0 Billion by 2030

The global market for Fluid Biopsy estimated at US$11.4 Billion in the year 2024, is expected to reach US$21.0 Billion by 2030, growing at a CAGR of 10.6% over the analysis period 2024-2030. Lung Cancer, one of the segments analyzed in the report, is expected to record a 12.4% CAGR and reach US$8.2 Billion by the end of the analysis period. Growth in the Breast Cancer segment is estimated at 8.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.1 Billion While China is Forecast to Grow at 14.7% CAGR

The Fluid Biopsy market in the U.S. is estimated at US$3.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.4 Billion by the year 2030 trailing a CAGR of 14.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.5% and 9.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

Global Fluid Biopsy Market - Key Trends & Drivers Summarized

Why Is Fluid Biopsy Emerging as a Disruptive Force in Cancer Diagnostics?

Fluid biopsy-also known as liquid biopsy-is transforming cancer diagnostics and disease monitoring by offering a non-invasive alternative to traditional tissue biopsies. By analyzing tumor-derived components such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and microRNAs from biological fluids (mainly blood), fluid biopsy enables early cancer detection, real-time disease tracking, and therapeutic response assessment. Its ability to capture tumor heterogeneity without the need for surgical sampling is particularly valuable in metastatic and inaccessible tumor settings.

This approach is gaining prominence in oncology due to its potential for detecting minimal residual disease (MRD), identifying actionable mutations, and guiding personalized therapy decisions across various cancer types-particularly lung, breast, colorectal, and prostate cancers. Unlike tissue biopsies that may be limited by procedural risks and spatial constraints, fluid biopsy allows for repeatable sampling over the disease course. As precision medicine continues to evolve, fluid biopsy is becoming an essential tool for dynamic tumor profiling and treatment adjustment.

What Technological Innovations Are Expanding the Potential of Fluid Biopsies?

Technological advancements in molecular biology, genomic sequencing, and digital PCR have significantly expanded the accuracy and clinical utility of fluid biopsies. Next-generation sequencing (NGS) platforms can now detect low-frequency mutations in ctDNA with high sensitivity, enabling early identification of tumor-related genomic alterations. Droplet digital PCR (ddPCR) and BEAMing (Beads, Emulsion, Amplification, Magnetics) are being utilized for mutation quantification, allowing for longitudinal tracking of tumor burden and therapy response.

Microfluidics-based platforms and CTC enrichment technologies are improving the capture efficiency of rare cells and particles from blood samples. Simultaneously, AI-driven data interpretation tools are facilitating rapid analysis of complex molecular signatures, supporting real-time clinical decision-making. Advances in multiplexing and integration of biomarkers from multiple fluid types-including urine, cerebrospinal fluid, and saliva-are extending fluid biopsy’s applications beyond oncology into other domains such as prenatal screening, organ transplant monitoring, and infectious disease surveillance.

Which Clinical and Therapeutic Areas Are Accelerating Adoption of Fluid Biopsy?

Fluid biopsy is primarily utilized in oncology, where it supports early cancer screening, companion diagnostics, and resistance mutation detection. In non-small cell lung cancer (NSCLC), for example, fluid biopsy is routinely used to detect EGFR mutations and guide the use of targeted therapies. Breast and prostate cancers are also key areas where serial fluid biopsies help monitor hormone receptor status and metastatic progression without repeated imaging or surgery.

Beyond solid tumors, hematological malignancies are beginning to benefit from ctDNA-based minimal residual disease detection, particularly in leukemias and lymphomas. Clinical trials now commonly incorporate fluid biopsy endpoints to stratify patients, evaluate drug efficacy, and correlate molecular response with clinical outcomes. Meanwhile, its application in immuno-oncology is expanding as researchers use fluid biopsy to assess tumor mutational burden (TMB) and predict response to checkpoint inhibitors. The versatility and scalability of fluid biopsy are also enabling broader adoption in population screening initiatives and point-of-care diagnostic frameworks.

What Are the Main Drivers Supporting Growth in the Fluid Biopsy Market?

The growth in the fluid biopsy market is driven by several converging factors rooted in clinical utility, technological maturity, and healthcare system needs. A primary driver is the growing demand for non-invasive, patient-friendly diagnostic tools that reduce procedure-related complications and enable frequent disease monitoring. This aligns with global trends favoring personalized medicine, early intervention, and outcomes-based treatment models.

The increasing availability of advanced sequencing technologies at lower costs is making fluid biopsy more accessible to both clinicians and diagnostic laboratories. Rising cancer incidence worldwide, combined with the need for timely, molecular-level decision support, is accelerating clinical adoption. Regulatory approvals for liquid biopsy-based companion diagnostics and reimbursement support in key markets are further solidifying its role in standard oncology workflows. Additionally, robust investments in precision oncology research, biopharma collaborations, and startup innovation are fueling a dynamic and competitive ecosystem that continues to expand the frontiers of fluid biopsy applications. Collectively, these drivers position fluid biopsy as a transformative force in the future of disease detection and personalized treatment.

SCOPE OF STUDY:

The report analyzes the Fluid Biopsy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Other Indications); Type (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â